Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Interview with Dr. Ashley Leech on the potential implications of Medicare Part D covering medications for obesity treatment. (11:22)Download Medicare could soon be compelled to cover antiobesity medications, which intensifies the need to address questions of effectiveness and cost among its beneficiaries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, limited payer coverage of antiobesity medications and off-label use of antidiabetes medications, including GLP-1 RAs, still represents a major challenge for many patients.16,17,18”
From Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity (2025) · cites this paper as [16]
Citations
Cites
Association of body mass index with health care expenditures in the united states by age and sex
Ward, Z. J., Bleich, S. N., Long, M. W., & Gortmaker, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247307 · Cited by 428
Risk of Progression to Diabetes Among Older Adults With Prediabetes
Rooney, M. R., Rawlings, A. M., Pankow, J. S., Echouffo Tcheugui, J. B., Coresh, J., Sharrett, A. R., & Selvin, E. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.8774 · Cited by 174
Dorner, B., & Friedrich, E. K. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.01.022 · Cited by 103
Research works printed but not linked: 1
- Atlas SJ Kim K Beinfeld M et al. Obesity management: an assessment of subcutaneous semaglutide phentermine/topiramate and naltrexone/bupropion. Boston: Institute for Clinical and Economic Review October 20 2022 (https://icer.org/assessment/obesity-management-2022/).
Cited by
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 344
“78,119,120 The past adoption trends of treatments for other metabolic diseases, such as statins for dyslipidaemia, suggest that although prescription volumes increased after introducing cheaper generic options, 121 considerable underutilisation remains in susceptible populations.”
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
Watanabe, J. H., Kwon, J., Nan, B., & Reikes, A. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.002 · Cited by 216
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sen, S., Potnuru, P. P., Hernandez, N., Goehl, C., Praestholm, C., Sridhar, S., & Nwokolo, O. O. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.0111 · Cited by 202
Metadata
- Authors
- Baig, K., Dusetzina, S. B., Kim, D. D., & Leech, A. A.
- Affiliations
- Vanderbilt University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-03-16
- Volume
- 388
- Issue
- 11
- Pages
- 961-963
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323925813
- Cited by
- 66
- References
- 3
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 26 · 2023: 17
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- Medicare Part D, anti-obesity drugs, obesity treatment, drug coverage, drug effectiveness, Medicare beneficiaries
- MeSH terms
- Aged, Humans, United States, Anti-Obesity Agents, Insurance Coverage, Uncertainty, Medicare Part D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.